Lifecare s implant continues to track glucose where traditional CGMs reach their limits

13 Jan 2026 07:00 CET

Bergen, Norway, 13 January 2026 - Lifecare ASA (LIFE) today reports new
findings from its ongoing longevity study LFC-SEN-002, showing that the
company's implantable glucose sensor continues to track glucose changes at
high levels where traditional enzyme-based CGM systems experience reduced
resolution.

Last week, Lifecare confirmed that its reproducibly manufactured, fully
integrated implant tracks glucose in vivo. This new analysis explains why that
matters.

A built-in system advantage
Lifecare's implant measures glucose using a non-enzymatic sensing principle
based on osmotic pressure - a natural biological and physical process that
scales with concentration. Because the system does not rely on enzyme
chemistry, it is not exposed to the same saturation effects that can limit
enzyme-based CGMs at high glucose levels.

In practical terms, this means Lifecare's implant continues to show clear and
structured glucose-related signals, even when glucose levels are very high.

Analysis of in-vivo data shows that the implant signal:

* remains directional and structured,
* continues to differentiate glucose changes,
* and behaves consistently with physiological expectations.

What this means
These findings support qualitative interpretation of glucose behaviour, such
as distinguishing very high from less high glucose states. Lifecare
does not make claims at this stage regarding numerical accuracy, clinical
performance, or diagnostic use. Remaining system-level work is focused
on optimisation and refinement.

"Because our system does not depend on enzyme reactions, it behaves
differently by design," says Joacim Holter, CEO of Lifecare. "What we are
seeing is exactly what we would expect from a non-enzymatic sensing principle:
the signal continues to behave coherently even at high glucose levels."

A clear step forward
This analysis builds directly on the system-level confirmation announced on 8
January 2026 and strengthens Lifecare's confidence in the robustness and
scalability of its implantable CGM platform.

Data from LFC-SEN-002 continue to support:

* further optimisation of long-term stability,
* preparation for veterinary market entry, and
* progress toward first-in-human studies and CE marking.

About LFC-SEN-002
LFC-SEN-002 is an ongoing longevity and performance study evaluating
Lifecare's implantable CGM technology in dogs. The study focuses on
biocompatibility, system stability and in-vivo signal behaviour, and supports
both veterinary product development and future human clinical programs. The
study is conducted under veterinary supervision in cooperation with
the Faculty of Veterinary Medicine, Department of Companion Animal Clinical
Sciences at the Norwegian University of Life Sciences. Data generated in the
study provide direct input to Lifecare's ongoing development and execution
program.

About us
Lifecare ASA is a medical sensor company developing technology for sensing and
monitoring of various body analytes. Lifecare's focus is to bring the next
generation of Continuous Glucose Monitoring systems to market. Lifecare
enables osmotic pressure as sensing principle. Lifecare's sensor technology is
suitable for identifying and monitoring the occurrence of a wide range of
analytes and molecules in the human body and in pets.

Contacts
For further information, please contact:

Joacim Holter, CEO, joacim.holter@lifecare.no, +47 40 05 90 40

Renete Kaarvik, CFO, renete.kaarvik@lifecare.no, +47 94 83 82 42

More information:
Access the news on Oslo Bors NewsWeb site

663498_Lifecare s implant continues to track glucose where traditional CGMs reach their limits.pdf